Actemra (tocilizumab) Letter of Medical Necessity
Actemra (tocilizumab) is denied at high rates when payers require failed TNF inhibitor therapy first or when site-of-care policies redirect infusions. A well-documented Letter of Medical Necessity addressing prior therapy and clinical rationale for IL-6 blockade resolves most appeals.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● giant cell arteritis
- ● systemic juvenile idiopathic arthritis
- ● polyarticular juvenile idiopathic arthritis
- ● cytokine release syndrome
- ● systemic sclerosis-associated interstitial lung disease
Why Actemra Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: TNF inhibitor not tried first for RA
- 2. Biosimilar (Tyenne, Tofidence) preferred on formulary
- 3. Active infection screening (TB, hepatitis B) not documented
- 4. Disease activity score (DAS28, CDAI) not on file
- 5. Site-of-care policy: hospital outpatient denied, home infusion or office required
What to Include in a Actemra Letter of Medical Necessity
For RA, document confirmed diagnosis with seropositivity (RF, anti-CCP) when applicable, prior csDMARD trial (methotrexate ≥3 months), prior TNF inhibitor failure or contraindication, current DAS28/CDAI, and TB/hepatitis screening. For GCA, document temporal artery biopsy or imaging findings, ESR/CRP, and inability to taper prednisone below 7.5 mg/day.
Key clinical evidence to cite:
- ✓ OPTION, TOWARD, RADIATE, AMBITION trials — RA efficacy
- ✓ GiACTA trial — superior remission in giant cell arteritis vs prednisone taper
- ✓ focuSSced trial — slowed FVC decline in SSc-ILD
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines
- 📖 ACR/VF 2021 Giant Cell Arteritis Guidelines
- 📖 ACR 2022 JIA Guidelines
Actemra Prior Authorization Criteria
Standard criteria across major US payers for Actemra. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: TNF inhibitor not tried first for RA
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Actemra
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Actemra Prior Authorization FAQ
Why was my Actemra prior authorization denied?
The most common denial reasons for Actemra are: Step therapy: TNF inhibitor not tried first for RA; Biosimilar (Tyenne, Tofidence) preferred on formulary; Active infection screening (TB, hepatitis B) not documented; Disease activity score (DAS28, CDAI) not on file; Site-of-care policy: hospital outpatient denied, home infusion or office required.
What should a Actemra Letter of Medical Necessity include?
For RA, document confirmed diagnosis with seropositivity (RF, anti-CCP) when applicable, prior csDMARD trial (methotrexate ≥3 months), prior TNF inhibitor failure or contraindication, current DAS28/CDAI, and TB/hepatitis screening. For GCA, document temporal artery biopsy or imaging findings, ESR/CRP, and inability to taper prednisone below 7.5 mg/day.
Which payers cover Actemra?
Actemra is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.